Clinical potential of gene mutations in lung cancer

摘要: Lung cancer is the most common type worldwide and leading cause of related deaths in United States. The majority newly diagnosed patients present with late stage metastatic lung that inoperable resistant to therapies. High-throughput genomic technologies have made identification genetic mutations promote progression possible. Identification drive provided new targets for non-small cell (NSCLC) treatment led development targeted therapies such as tyrosine kinase inhibitors can be used combat molecular changes progression. Development not only clinical benefit gene analysis studies. Biomarkers identified from early detection, determine patient’s prognosis response therapy, monitor disease identify NSCLC patient population would (targeted or chemotherapies), providing clinicians tools develop a personalized plan. This review explores potential studies on diagnosing treating NSCLC.